AUTHORS
Zachary R Hunter, PhD, Nickolas Tsakmaklis2, Alberto Guijosa, MD3, Andres Ramirez-Gamero, MD4, Amanda Kofides, MSc5, Maria Luisa Guerrera, MD6, Shirong Liu, PhD7, Hao Sun, MD, PhD8, Christopher Patterson, MBA, MPH9, Hanla Park10, James McKay, PhD11, Patrizia Mondello, MD, PhD12, Sonja Berndt, PhD13, Shayna Sarosiek, MD14, Jorge J Castillo, MD15, Steven Treon, MD, PhD16
AFFILIATIONS
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 International Agency for Research on Cancer, Lyon, France
11 International Agency for Research on Cancer/World Health Organization (IARC/WHO), Lyon, France
12 Mayo Clinic-Rochester, Rochester, Minnesota, United States
13 National Cancer Institute / National Institute of Health, Bethesda, Maryland, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
16 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ABSTRACT
Background Familial Waldenstrom macroglobulinemia (WM) was first described over 60 years ago (Masari, et al Nature 1962), while more recent studies restricting analysis to first- and second-degree relatives have documented a family history of related B-cell disorders (BCH) in ~ 20% of WM cases and a history of WM itself (WMH) in ~5% of cases (Treon et al, Ann. Oncol. 2006; 17(3):488-494). Genome wide association studies of WM and healthy donors previously identified genetic susceptibility loci at 6p25.3 and 14q32.13 (McMaster et al, Nat. Com. 2018; 9(1):4182). A recent NIH collaborative study confirmed and expanded on these findings (Park et al, Blood 2024; 144 (S1): 4358). While both markers are strongly associated with WM, no data on their association with familial WM predisposition is available. We therefore sought to analyze these two loci in the context of WM familial history and look for associated gene expression changes using an extensive multi-omics data set of untreated patients with WM (Hunter et al Blood 2023; 142(S1): 756).
Methods The study was performed as a collaborative NIH study. The previously identified 6p (rs116446171) and 14q (rs117972357) single nucleotide polymorphisms (SNP) were imputed for 915 WM patients from the Bing Center at the Dana-Farber Cancer Institute using Illumina SNP arrays. Family history of cancer was obtained for 913 of these patients. Genotyping and familial history were also available for 213 untreated patients with existing RNASeq data. These findings were validated by TaqMan genotyping assays and Sanger sequencing which were also used to expand the cohort to include additional patients with WMH for validation.
Results In line with previously published results, the variant allele frequency (VAF) for the 6p SNP was 0.1082 and the 14q SNP was 0.0814 in WM, both of which were significantly enriched compared with the reported VAF in European controls (0.0146 and 0.0027, respectively). No association was observed with molecular WM subtypes, patient sex or age of diagnosis for either marker. A strong association between familial history and 14q SNP genotype was seen with 88/675 (13%), 27/168 (16.1%) and 34/70 (48.6%) of patients with sporadic WM (no family history), BCH and WMH, respectively (p<0.0001). In all cases, 14q SNP was heterozygous. Conversely, no familial association was observed for the 6p marker wherein 135/675 (20%), 38/168 (22.6%), and 15/70 (21%) of patients carried at least one alternative allele in sporadic, BCH, and WMH patients, respectively (p=NS). Multiclonal spikes by serum protein electrophoresis (SPEP) were associated in those with the 14q SNP (5/33; 15.2%) versus those without (8/193; 4.1%); p=0.026. A significant anti-correlation was observed between the 14q and 6p SNPs where patients heterozygous for 14q had a VAF for 6p of 0.065 while those who were WT were 0.175 (p<0.0001). To validate these findings, DNA from 6 WMH families with siblings or parent/child pairs of WM patients were selected for validation. All index patients and 4 of 5 paired samples with available DNA tested positive for 14q SNP while none tested positive for 6p SNP. Differential gene expression of WM samples based on 14q SNP yielded no significant results. An association with HLA-DRB5 expression was seen with 6p SNP. The expression of HLA-DRB5 was notable for modal expression level patterns consistent with copy number variation. WM patients harboring the 6p SNP had expression levels of HLA-DRB5 similar to healthy donors while those wild-type for the 6p SNP showed elevated levels of HLA-DRB5 (p= 0.0879). This was partially explained by the significant upregulation of HLA-DRB5 in the WMH (p=0.0075) cohort and those with the 14q SNP (p=0.0016) which were enriched in the wild-type 6p SNP cohort.
Conclusions In this largest study to date focused on familial WM predisposition, GWAS identified SNP variants in 6p (rs116446171) and 14q (rs117972357) that are strongly associated with WM. The 14q SNP was strongly associated with WMH and multiclonal disease. Elevated HLA-DRB5 expression was associated with WMH and 14q SNP consistent with increased copy number. Further studies including whole genome sequencing to delineate the underlying genomic events responsible for these observations are underway and will be updated at the meeting.
DISCLOSURES
Zachary R Hunter, PhD: No relevant conflicts of interest to declare.